NCT00559533View on ClinicalTrials.gov

A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Neoplasms
Interventions
DRUG

RO5045337

Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)

Trial Locations (7)

10065

New York

33076

Bordeaux

69373

Lyon

77030

Houston

80045

Aurora

98229

San Antonio

02115

Boston

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00559533 - A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter